Castle Biosciences (CSTL)
Provides clinician-facing molecular diagnostic tests across dermatology and gastroenterology.
$34.85
After hours+0.02 (+0.06%)
At close$34.83(−0.46%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61 | 66 | 73 | 87 | 86 | 86 | 88 | 86 | 83 | 87 | 84 | 104 |
| Cost of revenue | 11 | 12 | 14 | 15 | 16 | 16 | 16 | 18 | 19 | 18 | 21 | 24 |
| Gross profit | 50 | 54 | 59 | 72 | 70 | 70 | 72 | 69 | 64 | 69 | 63 | 80 |
| 60 | 59 | 65 | 67 | 65 | 66 | 100 | 73 | 71 | 73 | 82 | 83 | |
| Research & development | 13 | 13 | 14 | 14 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 15 |
| 45 | 44 | 48 | 51 | 50 | 50 | 59 | 58 | 56 | 57 | 65 | 66 | |
| Selling & marketing | 28 | 27 | 31 | 33 | 30 | 30 | 37 | 35 | 33 | 33 | 41 | 41 |
| General & administrative | 16 | 17 | 18 | 18 | 21 | 20 | 22 | 23 | 23 | 23 | 24 | 25 |
| Other expenses | 2 | 2 | 2 | 2 | 2 | 4 | 28 | 2 | 2 | 2 | 2 | 2 |
| Operating income | −10 | −6 | −5 | 5 | 5 | 4 | −28 | −4 | −7 | −4 | −18 | −3 |
| 3 | 3 | 3 | 3 | 3 | 4 | 2 | 4 | 6 | 1 | 4 | 1 | |
| Interest income | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −3 | −3 | −3 | −3 | −3 | −4 | −2 | −4 | −6 | −1 | −4 | −2 |
| Income before tax | −7 | −3 | −2 | 8 | 8 | 8 | −26 | 0 | 0 | −3 | −14 | −2 |
| Income tax expense | 0 | 0 | 0 | −1 | 6 | −2 | 0 | −5 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −7 | −3 | −3 | 9 | 2 | 10 | −26 | 5 | −1 | −2 | −15 | −2 |
| Net income | −7 | −3 | −3 | 9 | 2 | 10 | −26 | 5 | −1 | −2 | −15 | −2 |
| EPS, basic | −$0.26 | −$0.10 | −$0.09 | $0.32 | $0.08 | $0.34 | −$0.90 | $0.16 | −$0.02 | −$0.08 | −$0.49 | −$0.07 |
| EPS, diluted | −$0.26 | −$0.10 | −$0.09 | $0.31 | $0.08 | $0.32 | −$0.90 | $0.15 | −$0.02 | −$0.08 | −$0.49 | −$0.07 |
| Weighted average shares, basic | 27 | 27 | 27 | 28 | 28 | 28 | 29 | 29 | 25 | 29 | 30 | 30 |
| Weighted average shares, diluted | 27 | 27 | 27 | 29 | 29 | 30 | 29 | 30 | 29 | 29 | 30 | 30 |
| EBITDA | −4 | 1 | 1 | 12 | 12 | 14 | 4 | 3 | 3 | 1 | −10 | 3 |
| Depreciation & amortization | 3 | 3 | 3 | 3 | 4 | 6 | 30 | 3 | 4 | 4 | 4 | 4 |
| EBIT | −7 | −3 | −2 | 8 | 8 | 8 | −26 | 0 | 0 | −3 | −14 | −1 |